Showing results (21-30 of 553) with videos related to
Sort By:
Pageof 56
Drugs in Context|April 25, 2022
Tofacitinib and newer JAK inhibitors in inflammatory bowel disease-where we are and where we are goingEleanor Liu, Nasar Aslam, Gaurav Nigam, et al.Drugs in Context|June 19, 2019
Easyhaler®: an overview of an inhaler device for day-to-day use in patients with asthma and chronic obstructive pulmonary diseaseFederico LavoriniDrugs in Context|July 2, 2019
Use of botulinum toxin for movement disordersCarlos Henrique Ferreira Camargo, Hélio Afonso Ghizoni TeiveDrugs in Context|February 11, 2022
Dabigatran in patients with atrial fibrillation after COVID-19 hospitalization: an update of the ANIBAL protocolJuan José Cerezo-Manchado, Olga Meca Birlanga, Luis García de Guadiana Romualdo, et al.Drugs in Context|February 11, 2022
Infectious disease: how to manage Gram-positive and Gram-negative pathogen conundrums with dual beta-lactam therapyAlireza FakhriRavari, Brenda Simiyu, Taylor Morrisette, et al.Drugs in Context|March 21, 2022
Open-label use of an aliphatic polyamine immunomodulator in patients hospitalized with COVID-19Sergey V Efimov, Natallia V Matsiyeuskaya, Olga V Boytsova, et al.Drugs in Context|April 4, 2022
Paediatrics: how to manage pediculosis capitisAlexander K C Leung, Joseph M Lam, Kin Fon Leong, et al.Drugs in Context|June 15, 2018
Immunotherapy in renal cell carcinoma: latest evidence and clinical implicationsMatteo Santoni, Francesco Massari, Vincenzo Di Nunno, et al.Drugs in Context|April 7, 2018
Treatment of diverticular disease: an update on latest evidence and clinical implicationsMarilia Carabotti, Bruno AnnibaleDrugs in Context|July 20, 2018
First-line alectinib for ALK-positive lung cancer: is there room for further improvement?Alfredo Addeo, Giulio MetroPageof 56